{"id":"ventolin-mdi","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Tremor"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Nervousness or anxiety"},{"rate":"1-5","effect":"Palpitations"},{"rate":"1-5","effect":"Muscle cramps"},{"rate":"1-5","effect":"Tachycardia"}]},"_chembl":{"chemblId":"CHEMBL1588467","moleculeType":"Small molecule","molecularWeight":"332.31"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Albuterol binds to beta-2 adrenergic receptors on bronchial smooth muscle cells, activating intracellular signaling that increases cAMP levels and causes muscle relaxation. This bronchodilation rapidly opens constricted airways, providing quick relief of acute asthma symptoms and shortness of breath. The metered-dose inhaler (MDI) formulation delivers the drug directly to the lungs for rapid local action.","oneSentence":"Ventolin MDI delivers albuterol (salbutamol), a beta-2 adrenergic agonist that relaxes airway smooth muscle to rapidly relieve bronchospasm and improve airflow.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:40:26.962Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute asthma exacerbation and bronchospasm relief"},{"name":"Maintenance therapy for asthma and chronic obstructive pulmonary disease (COPD)"}]},"trialDetails":[{"nctId":"NCT06644924","phase":"PHASE2","title":"A Study Evaluating the Effect of Inhaled PT007(AS MDI) Versus Placebo MDI and Ventolin Evohaler on Lung Function in Adult Participants With Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2025-02-10","conditions":"Asthma","enrollment":118},{"nctId":"NCT06816342","phase":"PHASE4","title":"Assessment of Emergency Spacers Versus Traditional Spacers for Delivery of Aerosolized Drugs","status":"RECRUITING","sponsor":"Beni-Suef University","startDate":"2024-11-01","conditions":"Asthmatic Patients, MDI, Aerosol Generating Procedure","enrollment":120},{"nctId":"NCT03924635","phase":"PHASE4","title":"An Exploratory Study to Characterise Changes in Airway Inflammation, Symptoms, Lung Function and Reliever Use in Adult Asthma Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2019-08-01","conditions":"Airway Inflammation, Asthma","enrollment":42},{"nctId":"NCT02741271","phase":"PHASE3","title":"Study of Efficacy and Long-Term Safety of Mometasone Furoate in Combination With Formoterol Fumarate Versus Mometasone Furoate in Children (5 to 11 Years of Age) With Persistent Asthma (MK-0887A-087)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2016-05-11","conditions":"Asthma","enrollment":181},{"nctId":"NCT00388882","phase":"PHASE4","title":"Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent® Inhalation Aerosol in COPD Patients.","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2006-10-04","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":327},{"nctId":"NCT05084222","phase":"PHASE4","title":"Use of Buventol Easyhaler and Bufomix Easyhaler in Methacoline Challenge Testing","status":"COMPLETED","sponsor":"Orion Corporation, Orion Pharma","startDate":"2021-11-11","conditions":"Asthma","enrollment":180},{"nctId":"NCT04848662","phase":"PHASE1","title":"To Compare the Pharmacokinetics of Budesonide Delivered by BDA MDI to Budesonide Delivered by Pulmicort Respules in Children With Asthma Aged 4 to 8 Years.","status":"COMPLETED","sponsor":"Bond Avillion 2 Development LP","startDate":"2021-05-06","conditions":"Asthma","enrollment":12},{"nctId":"NCT01615874","phase":"PHASE2","title":"Study of the Effect of Mometasone Furoate/Formoterol (MF/F), Montelukast and Beclomethasone Dipropionate (BDP) on Plasma Cortisol Levels of Children 5-11 Years Old With Persistent Asthma (P05574)","status":"WITHDRAWN","sponsor":"Organon and Co","startDate":"2013-01","conditions":"Asthma","enrollment":""},{"nctId":"NCT01899144","phase":"PHASE2","title":"Efficacy and Safety Comparison of Albuterol Spiromax® and ProAir® Hydrofluoroalkane (HFA) in Pediatric Patients","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-07","conditions":"Asthma","enrollment":61},{"nctId":"NCT00577655","phase":"PHASE3","title":"Albuterol HFA MDI in Pediatric Participants With Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2007-08","conditions":"Asthma","enrollment":103},{"nctId":"NCT01058863","phase":"PHASE2","title":"A Dose-ranging Study to Evaluate Albuterol and Hydrofluoroalkane in Subjects Ages 12 and Older With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2010-02","conditions":"Asthma","enrollment":72},{"nctId":"NCT02040766","phase":"PHASE3","title":"A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants Ages 4-11 Years Old With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-12","conditions":"Asthma","enrollment":628},{"nctId":"NCT02513160","phase":"PHASE3","title":"Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate in Adolescent and Adult Patients 12 Years of Age and Older With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2015-09-30","conditions":"Persistent Asthma","enrollment":713},{"nctId":"NCT03012061","phase":"PHASE2","title":"Phase IIb Study of Umeclidinium (UMEC) Bromide Versus Placebo in Subjects With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-01-25","conditions":"Asthma","enrollment":425},{"nctId":"NCT03364608","phase":"PHASE2","title":"Study to Compare PT007 to Placebo MDI and Open-Label Proventil® HFA in Adult and Adolescent Subjects With Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-12-15","conditions":"Asthma","enrollment":86},{"nctId":"NCT03371459","phase":"PHASE2","title":"Assessment of the Safety, Efficacy, PK, and Extrapulmonary Pharmacodynamics (PD) of Albuterol Sulfate Pressurized Inhalation Suspension (Hereafter Referred to as AS MDI) Compared to Proventil as an Active Control in Subjects With Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-12-29","conditions":"Asthma","enrollment":46},{"nctId":"NCT02499887","phase":"NA","title":"Repeat Emergency Department Visits Among Patients With Asthma and COPD","status":"TERMINATED","sponsor":"State University of New York at Buffalo","startDate":"2016-01","conditions":"Asthma, COPD","enrollment":6},{"nctId":"NCT01576718","phase":"PHASE2","title":"A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler (Puffer) in Adolescents and Adults Who Have Asthma That is Not Controlled by High Dose Inhaled Corticosteroid Asthma Medications","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2012-04","conditions":"Asthma","enrollment":889},{"nctId":"NCT02433834","phase":"PHASE2","title":"Chronic Dosing Cross-Over Study to Assess the Efficacy and Safety of Glycopyrronium (PT001) in Adult Subjects With Intermittent Asthma or Mild to Moderate Persistent Asthma","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2015-05-27","conditions":"Asthma","enrollment":248},{"nctId":"NCT01479621","phase":"PHASE2","title":"A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler in Adolescents and Adults Who Have Asthma That is Not Controlled by Asthma Medications Not Containing Steroids","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2012-01","conditions":"Asthma","enrollment":909},{"nctId":"NCT02210806","phase":"PHASE2","title":"Albuterol DPI (A006) Clinical Study-B3:Efficacy, Dose-ranging and Safety Evaluation","status":"COMPLETED","sponsor":"Amphastar Pharmaceuticals, Inc.","startDate":"2014-07","conditions":"Asthma","enrollment":22},{"nctId":"NCT02271334","phase":"PHASE2","title":"Evaluation of Pharmacokinetics and Safety of A006 in Healthy Volunteers","status":"COMPLETED","sponsor":"Amphastar Pharmaceuticals, Inc.","startDate":"2014-08","conditions":"Asthma","enrollment":22},{"nctId":"NCT00605891","phase":"PHASE2","title":"Dose Finding Study of CHF 4226 for Treating Patients With COPD","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2006-10","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":278},{"nctId":"NCT02319564","phase":"PHASE4","title":"Combined Glucocorticoid Adrenergic Therapy For Wheezy Preschool Children","status":"WITHDRAWN","sponsor":"University of Calgary","startDate":"2016-04","conditions":"Wheeze","enrollment":""},{"nctId":"NCT02150499","phase":"PHASE3","title":"A Study of Levalbuterol Tartrate HFA Inhalation Aerosol Metered Dose Inhaler (MDI) in Pediatric Subjects","status":"TERMINATED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2014-07","conditions":"Asthma","enrollment":18},{"nctId":"NCT01424813","phase":"PHASE3","title":"A 12-week Study to Compare the Efficacy and Safety of Albuterol Spiromax® Versus a Placebo in People 12 Years and Older With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2012-12","conditions":"Asthma","enrollment":158},{"nctId":"NCT01747629","phase":"PHASE3","title":"Efficacy of Inhaled Albuterol Spiromax® in Subjects With Persistent Asthma With Steady State Pharmacokinetics","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2012-12","conditions":"Asthma","enrollment":160},{"nctId":"NCT01218009","phase":"PHASE3","title":"A Twelve Month Long Term Safety Study to Evaluate the Safety of Albuterol in a Dry Powder Inhaler With Both Repeated and as Needed Dosing","status":"TERMINATED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2010-10","conditions":"Asthma","enrollment":331},{"nctId":"NCT01019694","phase":"PHASE3","title":"Combivent Respimat 1-year Safety Study in Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2009-11","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":470},{"nctId":"NCT02242253","phase":"PHASE2","title":"Free Combinations of Tiotropium Inhalation Powder Capsule + Salmeterol Metered Dose Inhaler, Tiotropium Inhalation Powder Capsule and Salmeterol Metered Dose Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2003-09","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":97},{"nctId":"NCT02173678","phase":"PHASE1","title":"Safety and Tolerability of COMBIVENT® HFA as Compared to COMBIVENT® CFC and Placebo HFA in Healthy Male and Female Subjects","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"1999-10","conditions":"Healthy","enrollment":12},{"nctId":"NCT00400153","phase":"PHASE3","title":"Respimat® Combivent Trial in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2006-11","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1480},{"nctId":"NCT00535366","phase":"PHASE2","title":"Efficacy and Safety Comparison of Steroid or Placebo in Combination With Salmeterol and Tiotropium in COPD","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2007-10","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":103},{"nctId":"NCT00096616","phase":"PHASE2","title":"Combivent® CFC Metered Dose Inhaler (MDI) in Moderate to Severe Asthma","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2004-11","conditions":"Asthma","enrollment":113},{"nctId":"NCT01795664","phase":"PHASE3","title":"Compare the Effects of Seretide® Evohaler and a Generic Salmeterol/Fluticasone Hydrofluoroalkane (HFA) Pressurized Metered-dose Inhaler (pMDI) on Functional Respiratory Imaging Parameters in Asthmatic Patients","status":"COMPLETED","sponsor":"FLUIDDA nv","startDate":"2013-03","conditions":"Asthma","enrollment":16},{"nctId":"NCT00545272","phase":"PHASE2","title":"A Dose Ranging Trial of 4 Doses of Indacaterol Delivered Via TWISTHALER® Device in Adult and Adolescent Patients With Persistent Asthma","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2007-10","conditions":"Asthma","enrollment":392},{"nctId":"NCT00557466","phase":"PHASE2","title":"A Dose Ranging Trial of 4 Doses of Indacaterol Delivered Via the TWISTHALER® Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-10","conditions":"COPD","enrollment":568},{"nctId":"NCT01096017","phase":"PHASE3","title":"To Investigate the Relative Efficacy of Terbutaline Turbuhaler® and Salbutamol Pressurized Metered Dose Inhaler (pMDI) a Single Blind Study","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-03","conditions":"Asthma","enrollment":24},{"nctId":"NCT00583986","phase":"PHASE3","title":"Reliability of a Top Mount Actuation Indicator With Levalbuterol MDI in Adult and Pediatric Subjects With Asthma or COPD","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2005-09","conditions":"Asthma, Chronic Obstructive Pulmonary Disease, COPD","enrollment":150},{"nctId":"NCT01112241","phase":"PHASE4","title":"Bronchodilator Responsiveness in Obliterative Bronchiolitis","status":"COMPLETED","sponsor":"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy","startDate":"2010-04","conditions":"Obliterative Bronchiolitis","enrollment":17},{"nctId":"NCT01076322","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Meptin® Swinghaler® and Ventolin® MDI in Stable Asthma Patients","status":"COMPLETED","sponsor":"Taiwan Otsuka Pharm. Co., Ltd","startDate":"2009-03","conditions":"Asthma","enrollment":17}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":9,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Ventolin® MDI","genericName":"Ventolin® MDI","companyName":"Taiwan Otsuka Pharm. Co., Ltd","companyId":"taiwan-otsuka-pharm-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ventolin MDI delivers albuterol (salbutamol), a beta-2 adrenergic agonist that relaxes airway smooth muscle to rapidly relieve bronchospasm and improve airflow. Used for Acute asthma exacerbation and bronchospasm relief, Maintenance therapy for asthma and chronic obstructive pulmonary disease (COPD).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}